An interventional study of Transcranial Magnetic Stimulation in Primary Progressive Aphasia, sponsored by Hospital San Carlos, Madrid. Completed at 1 site in Spain. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2020-05-14.
Sponsored by Hospital San Carlos, Madrid · Not applicable, Interventional, and Treatment
Primary progressive aphasia (PPA) is a clinical syndrome characterized by the neurodegeneration of language brain systems. Three main clinical variants are currently recorgnized (nonfluent, semantic, and logopenic PPA). Nowadays, there are no effective treatments for this disorder.
Transcranial Magnetic Stimulation (TMS) is a technique based on the principle of electromagnetic induction of an electric field in the brain. It has been used as a non-invasive therapy in different disorders, such as depression, bipolar disorder, Parkinson's disease, and in the rehabilitation of post-stroke aphasia. Recent studies have shown how repetitive TMS improved language characteristics in Alzheimer's disease, and there are initial data in patients with PPA.
This research project investigates the effect of repetitive TMS in patients with PPA. Investigators will perform a personalized TMS treatment for each patient (brain region, type of stimulation/inhibition, etc.), according to the specific characteristics of each patient and with the final aim to generate a computational model.
365 studies on the registry are indexed under Aphasia; 89 are open to participants now.
This study's enrollment of 20 is below the median of 30 across 316 interventional studies indexed under Aphasia.
Browse Aphasia studies →Hospital San Carlos, Madrid is the lead sponsor of 70 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Transcranial Magnetic Stimulation
Device: Transcranial Magnetic Stimulation
Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
Changes in spontaneous speech (main primary endpoint)
Picture and story description task
Time frame: 2 months (at baseline and at the end of the treatment)
Changes in oral naming
Object naming test
Time frame: 2 months
Changes in reading
Story and words reading test
Time frame: 2 months
Changes in repetition
Non-words and sentence repetition task
Time frame: 2 months (at baseline and at the end of the treatment)
Changes in brain metabolism
Brain metabolism measured using 18F-FDG-PET
Time frame: 2 months (at baseline and at the end of the treatment)
Changes in clinical impression of change
Patient's clinical impression of change (from 0 to 10)
Time frame: 2 months (at baseline and at the end of the treatment)
Changes in brain cortical electrical activity
Changes in the brain cortical electrical activity measured using quantitative electroencephalography (EEG)
Time frame: 2 months (at baseline and at the end of the treatment)
Changes in global cognition
Addenbrooke's Cognitive Examination III
Time frame: 2 months (at baseline and at the end of the study)
Changes in clinical impression of change
Caregiver's clinical impression of change (from 0 to 10)
Time frame: 2 months
Plan to share: Undecided
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital San Carlos, Madrid